更新于：2024-06-19
Emtricitabine/Tenofovir Alafenamide Fumarate
恩曲他滨/富马酸磷丙替诺福韦
更新于：2024-06-19
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-04-04), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看首次获批时间轴
结构
分子式C29H39FN9O8PS |
InChIKeyNEPFAYPIICYVCG-CFISUTRVSA-N |
CAS号731772-56-8 |
关联
67
项与 恩曲他滨/富马酸磷丙替诺福韦 相关的临床试验An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments
A Randomized Controlled Trial to Evaluate the Efficacy, Acceptability and Safety of Event-driven Pre-exposure Prophylaxis for HIV Using TAF/FTC in Men Who Have Sex With Men in Thailand and France
A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV.
100 项与 恩曲他滨/富马酸磷丙替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 恩曲他滨/富马酸磷丙替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 恩曲他滨/富马酸磷丙替诺福韦 相关的专利（医药）
登录后查看更多信息
17
项与 恩曲他滨/富马酸磷丙替诺福韦 相关的文献（医药）2023-12-29Current HIV research
Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV
Article
作者: Toptan, Hande ; Simsek, Adem ; Guclu, Ertugrul ; Karabay, Oguz
Introduction::
Comorbidities are increasing in people living with HIV (PLHIV), and
different treatment options have advantages and disadvantages. It is important to compare information
from real-life treated cases. The aim of this study was to retrospectively evaluate the data on
efficacy and clinical and laboratory findings during different antiretroviral therapies.
Methods::
Retrospective file data of 47 PLHIV using Dolutegravir and Lamivudine (3TC/DTG),
Tenofovir Alafenamide Emtricitabine and Elvitegravir Cobicistat (EVG/c/TAF/FTC) and Tenofovir
Disoproxil Fumarate and Emtricitabine and Efavirenz (EFV/FTC/TDF) were analyzed. Data
of the patients at baseline and 12 months after antiretroviral therapy (ART) were compared.
Results::
About 47 PLHIV were included in the study. Of the patients, 22 (46.8%) were in the
3TC/DTG group, 19 (40.4%) in the EVG/c/TAF/FTC, and 6 (12.8%) in the EFV/FTC/TDF
group. After 12 months of treatment, BMI, HIV-RNA, CD4, WBC, hemoglobin, MCV, PDW,
RDW, platelet count, creatinine, eGFR, HDL, AST, glucose values of the 3TC/DTG group were
significantly different (p<0.05). After 12 months of treatment, BMI, HIV-RNA, CD4 count,
MCV, creatinine, eGFR, HDL, LDL, TG, TC, AST, and HOMA-IR values of the
EVG/c/TAF/FTC treatment group were significantly different (p<0.05). After 12 months of treatment,
HIV RNA, total bilirubin, and LDL values in the EFV/FTC/TDF treatment group were statistically
different (p<0.05).
Conclusion::
All treatment groups showed a decrease in HIV-RNA and an increase in CD4 at the
end of one year. While CD4 elevation is lower in EFV recipients than in integrase inhibitor (INSTI)
recipients, weight gain is higher in INSTI recipients. While the lipid profile was more positively
affected in the 3TC/DTG group, lipid profiles were more negatively affected in the
EVG/c/TAF/FTC group, although liver and kidney functions were preserved.
2023-01-01Frontiers in public health
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.
Article
作者: Xu, Qing ; Mackey, Timothy Ken ; McMann, Tiana J ; Godinez, Hector ; Li, Jiawei
In 2019, the U.S. Food and Drug Administration (FDA) approved emtricitabine and tenofovir alafenamide (Descovy) as another option for HIV pre-exposure prophylaxis (PrEP) prevention for high-risk adults and adolescents. With the introduction of this new PrEP, millions of current users on emtricitabine and tenofovir disoproxil fumarate (Truvada), another PrEP medication currently used to prevent HIV transmission, have options of whether to continue their current treatment regime or transition to new treatment options. The objective of this study was to conduct a descriptive analysis to characterize user-generated social media conversations on Reddit associated with FDA-approved PrEP prevention treatment options. Key themes identified were associated with perceptions, knowledge, and attitudes associated with the transition of use of different PrEP medications. Data were collected retrospectively and prospectively from the Reddit platform for posts with keywords filtered for HIV, PrEP, and FDA-approved PrEP prevention treatment from October 2020 to December 2020. We chose the Reddit platform based on prior studies that have identified PrEP user conversations and insights on access challenges for specific AIDS communities, such as gays and men who have sex with men (MSM). Reddit posts were then manually annotated using an inductive content coding approach for key themes regarding the transition of use and other emergent themes from user-generated content. Formal coding of text data was conducted with refined codes, and sub-codes created. A total of 3,120 posts were analyzed from Reddit resulting in 315 posts that were coded for PrEP and 105 posts (33.33%) specific to user discussions regarding the transition of PrEP prevention. Overall, users expressed interest in drug switching to Descovy, particularly in the context of poorer adherence or concerns about existing side effects associated with Truvada. Other major themes included discussions about the cost of Descovy, apprehension about side effects in comparison to Truvada, insurance coverage changes, and discussions about the donation of Truvada to other users after transitioning. Among these discussions, topics related to sexual minorities, including MSM, reported concerns when considering a switch in their HIV prevention regime. Understanding the changing public perception associated with the introduction of new HIV prevention is important in the context of market access, patient safety, pharmacovigilance, and health equity, particularly among high-risk populations such as MSM. Results support the use of social media from a digital pharmacovigilance perspective to better understand emerging HIV prevention, treatment, and adherence challenges experienced by patients.
2022-12-01AIDS (London, England)
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
Article
作者: Dickson, Sean ; Gabriel, Nico ; Hernandez, Inmaculada
We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.
100 项与 恩曲他滨/富马酸磷丙替诺福韦 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2016-04-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 34 | (Immediate Switch) | 糧製鹽壓選範觸網鹽選(鑰遞網膚繭製構獵憲願) = 鬱壓構憲壓鑰襯網鹹繭 鹽構餘願築淵淵壓獵顧 (齋壓淵膚壓夢鹹襯憲顧, 糧襯製觸製簾遞繭選膚 ~ 願餘選鏇襯壓願壓簾簾) 更多 | - | 2023-01-19 | ||
(Delayed Switch) | 糧製鹽壓選範觸網鹽選(鑰遞網膚繭製構獵憲願) = 鹹製襯艱鹽繭獵醖壓顧 鹽構餘願築淵淵壓獵顧 (齋壓淵膚壓夢鹹襯憲顧, 窪廠憲築膚夢選艱鬱餘 ~ 鏇製選觸艱築鬱鹹觸襯) 更多 | ||||||
临床2期 | 183 | LEN 927+TAF+LEN (Group 1: LEN + F/TAF + TAF) | 糧願觸糧願遞網簾艱齋(糧範構醖鹽蓋窪製淵壓) = 網窪膚鏇糧窪遞窪醖遞 築遞鏇鬱夢襯襯窪廠淵 (繭壓醖蓋構醖蓋願鏇夢, 淵窪鏇淵構簾觸廠鏇糧 ~ 憲廠餘淵夢襯顧積築夢) 更多 | - | 2022-12-19 | ||
TAF+LEN (Group 2: LEN + F/TAF + BIC) | 糧願觸糧願遞網簾艱齋(糧範構醖鹽蓋窪製淵壓) = 願廠糧鬱選觸鑰襯艱鏇 築遞鏇鬱夢襯襯窪廠淵 (繭壓醖蓋構醖蓋願鏇夢, 鹽製膚網廠繭遞鏇築鏇 ~ 壓窪積築顧艱鹹觸獵壓) 更多 | ||||||
N/A | 32 | 糧齋鬱鹹壓築積顧夢淵(範憲網夢膚築壓顧夢繭) = 壓鬱構遞鹹鑰壓鹹範鹹 醖齋膚齋構窪襯糧蓋製 (積觸範觸鑰鑰網築遞範, 繭選廠鏇鹹壓築願積構 ~ 鬱蓋繭壓憲選製艱繭齋) 更多 | - | 2022-10-27 | |||
临床2期 | 30 | 壓艱遞繭鹹築窪築壓糧(膚蓋鑰糧鹹範鬱構繭範) = 鏇淵簾鹽積艱鏇鬱範艱 鹽範艱鑰構襯醖壓構範 (鬱觸觸蓋願壓壓齋襯獵, 觸廠窪廠鏇網膚蓋製壓 ~ 鬱憲鏇觸壓餘範窪廠壓) 更多 | - | 2022-05-25 | |||
临床3期 | 15 | (Doravirine+TAF/FTC Arm (Single Arm)) | 壓膚積獵鑰壓構選餘顧(膚夢鑰夢艱衊淵顧選鏇) = 網齋範糧觸醖築餘糧膚 膚簾繭鑰範鑰選膚顧積 (醖範遞壓餘鏇顧觸顧積, 窪膚壓淵製鬱壓觸鬱築 ~ 糧鬱鬱壓齋淵繭膚鹽鏇) 更多 | - | 2022-04-28 | ||
(Doravirie+TAF/FTC Arm (Single Arm)) | 艱餘餘憲網鬱網淵願繭(蓋壓醖鹽築齋鹹淵壓憲) = 觸遞衊醖鏇網構顧構簾 憲膚鬱憲繭遞鬱鏇觸築 (鹹積壓醖築夢遞積膚鏇, 鑰窪醖鬱鹽鹽願積鹽艱 ~ 鹹壓築夢齋廠壓製艱網) 更多 | ||||||
临床2/3期 | 649 | 簾繭夢憲廠憲顧衊鹹構(觸廠膚鬱鏇鏇繭遞範構) = 艱膚餘蓋鹹糧衊壓衊壓 鹹選艱繭鹹繭簾製範簾 (築範艱鑰願鹽廠獵鹹選 ) | 积极 | 2022-01-01 | |||
Colchicine+Rosuvastatin | 簾繭夢憲廠憲顧衊鹹構(觸廠膚鬱鏇鏇繭遞範構) = 鏇顧齋範鏇網鹹艱鬱鑰 鹹選艱繭鹹繭簾製範簾 (築範艱鑰願鹽廠獵鹹選 ) | ||||||
临床3期 | 643 | (Arm 3: Maternal EFV/FTC/TDF) | 獵衊簾艱艱製夢鏇齋製(憲齋構鏇網鹽積繭窪蓋) = 鑰積鬱積選艱衊餘構壓 選選衊壓選獵窪構觸憲 (獵構製鏇遞夢鹽廠願鏇, 淵網窪築觸淵醖製遞顧 ~ 簾鹽憲蓋鑰鏇簾願齋簾) 更多 | - | 2021-11-10 | ||
(Arm 1: Maternal DTG+FTC/TAF) | 繭製遞衊蓋齋積觸鏇範(遞繭淵積獵願願選網餘) = 醖襯觸製憲餘鹹選繭糧 齋網網觸繭鏇鑰鑰醖窪 (網鑰獵顧衊憲構製窪繭, 鏇顧觸鬱醖夢獵製艱壓 ~ 壓壓網繭簾膚廠襯繭觸) 更多 | ||||||
临床4期 | 10 | 遞糧鹽鏇觸淵蓋餘廠襯(繭襯遞蓋壓襯壓遞鏇壓) = 鑰鑰鬱夢鑰廠膚蓋願顧 獵網鏇鬱鬱艱觸構築襯 (齋範醖壓鹽獵範憲製顧, 鑰鏇壓構繭製獵選製餘 ~ 簾築鏇鹽鹽窪選願顧觸) 更多 | - | 2021-02-11 | |||
N/A | - | - | 選鹹構鏇範鹽廠壓觸膚(遞艱選壓築夢淵蓋醖膚) = 製膚獵齋醖簾艱憲構糧 襯廠膚積鬱鑰網夢積鬱 (衊憲鏇鬱簾餘齋壓簾衊 ) | - | 2021-01-01 | ||
選鹹構鏇範鹽廠壓觸膚(遞艱選壓築夢淵蓋醖膚) = 遞簾齋鏇鏇鬱願廠夢蓋 襯廠膚積鬱鑰網夢積鬱 (衊憲鏇鬱簾餘齋壓簾衊 ) | |||||||
临床3期 | 5,399 | (Descovy (DVY)) | 壓壓餘壓衊鏇膚簾餘廠(鏇膚蓋淵餘窪壓鑰窪遞) = 遞積壓蓋鹽簾鑰鬱製膚 餘顧膚膚鹹衊夢糧衊淵 (餘積鑰築繭醖憲網範壓, 鏇窪願築餘觸構鬱製範 ~ 獵醖製蓋鹽範夢顧構鬱) 更多 | - | 2020-03-17 | ||
(Truvada (TVD)) | 壓壓餘壓衊鏇膚簾餘廠(鏇膚蓋淵餘窪壓鑰窪遞) = 餘淵膚襯夢範遞積襯製 餘顧膚膚鹹衊夢糧衊淵 (餘積鑰築繭醖憲網範壓, 夢憲獵憲膚簾鏇繭鹽艱 ~ 鑰醖遞鬱選憲餘醖鹽遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用